How much TB-500 should I take?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds TB-500 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
A DailyMed search returned no TB-500 label and searches for a published human trial with a TB-500 dose returned none; a 2026 uncontrolled case report by Froum and colleagues, in three patients with nerve injury after dental surgery, gave TB-500 10 mg as weekly injections inside the mouth for 4 weeks, together with other agents.12
The guide's example
2.5 mg of TB-500 from a 10 mg vial mixed with 2 mL is 50 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg21% set up7 | 5 mg/mL: 1 mg is 20 units, 2 mg is 40 units, 2.5 mg is 50 units | 2.5 mg/mL: 1 mg is 40 units, 2 mg is 80 units, 2.5 mg is 100 units |
| 10 mg71% set up7 | 10 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 2.5 mg is 25 units | 5 mg/mL: 1 mg is 20 units, 2 mg is 40 units, 2.5 mg is 50 units |
How TB-500 vials are supplied and mixed
2.5 mg of TB-500 from a 10 mg vial mixed with 2 mL is 50 units on a U-100 syringe.
44% set up 10 mg + 2 mL7
The calculator is at the top of the page
FDA reports websites offering TB-500 as powder in 2, 3, 5, 10 and 15 mg vials, labelled for research use only.3 The product in the nomination FDA reviewed is a 3 mg/mL freeze-dried powder.3 Of the people who logged TB-500, 71% set up a 10 mg vial and 21% a 5 mg vial.7 A 10 mg + 2 mL mix was set up by 44% and 10 mg + 1 mL by 16%.7
FDA records one website giving reconstitution and administration instructions; none of the sources reviewed gives a label or manufacturer leaflet stating which water or how much.3 The table and the TB-500 calculator only work out concentration and syringe marks from the vial and water volume, and the steps are in the mixing guide.
What has been given to people
The searches run returned no label and no published human trial giving a TB-500 dose, schedule or cycle length. In its briefing for the July 2026 advisory committee, FDA states that neither form of TB-500 is part of an FDA-approved drug, and that its literature search found no article in which TB-500 was given to humans.3
| Record | Dose and schedule | People | Length |
|---|---|---|---|
| Case report, Froum and colleagues, 2026 | TB-500 10 mg weekly as injections inside the mouth, with ARA-290, BPC-157, dexamethasone and local anaesthetic2 | three patients with nerve injury after dental surgery | 4 weeks |
| Registry entry NCT07487363, Hudson Biotech, phase 1/2, recruiting | Dose levels not published; three sequential dose cohorts, TB-500 to placebo 3:14 | 80 adults with stable atherosclerotic cardiovascular disease, estimated | 8 weeks of dosing, 4 weeks of follow-up |
The case report's authors write that, owing to the uncontrolled nature of these observations, spontaneous recovery and other confounding factors cannot be excluded, and causality cannot be established.2 Other figures are not human TB-500 doses: in a horse study FDA cites (Ho and colleagues, 2012), thoroughbred geldings were given a single dose of TB-500 free base 10 mg under the skin, and in a 2026 study by Bicer and colleagues, thirty-two rats with a repaired Achilles tendon were split into four groups of eight, the TB-500 group getting 60 µg/kg/day into the abdominal cavity for four weeks.35 In a 2010 placebo-controlled study by Ruff and colleagues of thymosin beta-4, a different substance from TB-500, four cohorts of 10 healthy volunteers were given a single dose of 42, 140, 420 or 1260 mg by vein and then the same dose daily for 14 days.6
Of the people who logged TB-500, 77% logged doses in mg.7 Doses of 1 mg, 2 mg and 2.5 mg were each logged by 17%.7
How TB-500 is stored
For TB-500 free base powder, a product data sheet reported by FDA gives storage in a sealed container away from moisture and light, under nitrogen, at -80°C for 2 years or -20°C for a year.3 In solvent, the same data sheet gives storage in a sealed container away from moisture and light, under nitrogen, at -80°C for 6 months or -20°C for one month.3 For TB-500 acetate, FDA reports that the certificate of analysis submitted by the nominator recommends 2-8°C in a refrigerator or a freezer when stored in a sealed container.3 FDA adds that public-domain information gives below -15°C for TB-500 acetate, protected from light, in a tightly closed container.3 FDA gives no stability data for a mixed TB-500 vial and notes that peptides such as TB-500 can be extremely sensitive to formulation, process and environmental conditions such as pH and heat, which may lead to aggregation and degradation.3 FDA says multiple salts and derivatives, including different active moieties, are sold under the common name TB-500, and each storage figure above is reported for the form named.3
Frequently asked questions
Do people log TB-500 with BPC-157?
Of the people who logged TB-500, 86% also logged BPC-157; see the BPC-157 and TB-500 guide and the BPC-157 dosage guide.7
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- US National Library of Medicine. DailyMed label search for TB-500. 2026. dailymed.nlm.nih.gov
- Frontiers in Oral Health. Case Report: Regenerative peptides for inferior alveolar nerve injury (Froum et al.). 2026. ebi.ac.uk
- US Food and Drug Administration. FDA briefing document for TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. 2026. fda.gov
- ClinicalTrials.gov (sponsor Hudson Biotech). NCT07487363: TB-500 for cardiovascular biomarkers in stable ASCVD. 2026. clinicaltrials.gov
- Joint Diseases and Related Surgery. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (Bicer et al.), animal study. 2026. eutils.ncbi.nlm.nih.gov
- Annals of the New York Academy of Sciences. Intravenous thymosin beta4 in healthy volunteers (Ruff et al.), a different substance from TB-500. 2010. eutils.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted